Paul Oberstein, MD

Articles by Paul Oberstein, MD

Paul Oberstein, MD, discusses how RASolute 302 may be the most significant advance in pancreatic cancer treatment in more than a decade.

RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough

ByGina Mauro,Paul Oberstein, MD

July 24th 2026

Paul Oberstein, MD, discusses how RASolute 302 may be the most significant advance in pancreatic cancer treatment in more than a decade.

Latest Updated Articles

Trending on CancerNetwork

Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma

What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism

FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors

Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC

Perioperative Pembrolizumab Plus Chemo Does Not Significantly Improve EFS in MIBC